The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review
Author:
Funder
AbbVie
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s12325-021-01951-z.pdf
Reference89 articles.
1. Health Canada. Biosimilar biologic drugs in Canada: fact sheet. https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/Fact-Sheet-EN-2019-08-23.pdf. Accessed 24 Feb 2020
2. Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017;52(2):141–50. https://doi.org/10.1007/s00535-016-1283-0.
3. Codreanu C, Popescu CC, Mogosan C. Area of residence and socioeconomic factors reduce access to biologics for rheumatoid arthritis patients in Romania. Biomed Res Int. 2018;2018:7458361. https://doi.org/10.1155/2018/7458361.
4. Louis E. Stopping biologics in IBD—what is the evidence? Inflamm Bowel Dis. 2018;24(4):725–31. https://doi.org/10.1093/ibd/izx098.
5. Ooi CJ, Hilmi I, Banerjee R, et al. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia. J Gastroenterol Hepatol. 2019;34(8):1296–315. https://doi.org/10.1111/jgh.14648.
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Evolution of Pharmacological Treatments and Associated Costs for Multiple Myeloma in the Public Healthcare System of Catalonia: A Retrospective Observational Study;Cancers;2023-11-09
2. Author’s Response to Letter to the Editor - Re: Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin. 2022;38(4):613–627;Current Medical Research and Opinion;2022-11-07
3. Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations;Multiple Sclerosis Journal;2022-08-24
4. Pharmacoeconomic rationale for switching patients with rheumatic diseases from original biologic disease-modifying antirheumatic drugs to biosimilars in context of the Russian healthcare system;Modern Rheumatology Journal;2022-06-29
5. A review of biosimilars for rheumatoid arthritis;Current Opinion in Pharmacology;2022-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3